CompletedNot Applicable

The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy

United States7 participantsStarted 2017-11-27

Plain-language summary

In the setting of naloxone standing orders, this study will assess if co-dispensing naloxone with opioids to patients prescribed chronic opioid therapy changes opioid risk behaviors, increases naloxone uptake, and increases knowledge about overdose and naloxone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Study Population: * Eligible pharmacies * Patients prescribed chronic opioid therapy Inclusion Criteria for pharmacies: * Stock naloxone for outpatient dispensing. * Pharmacy leadership willing to provide naloxone under a co-dispensing protocol. * Pharmacy leadership willing to be randomized to order of implementation. * Have or can implement a naloxone standing order. Exclusion Criteria for pharmacies: • None Inclusion Criteria for patients: * Prescribed chronic opioid therapy and meet criteria for the pharmacy co-dispensing protocol * Receive medications at participating pharmacies * Have a health plan which covers the formulation of naloxone available at the pharmacy they received their opioid prescriptions from. * (for surveys)18 years of age or greater Exclusion Criteria: • (for surveys) Non-English speaking, hospice enrollment, do-not-resuscitate order

What they're measuring

Change in Opioid-Related Risk Behavior

Timeframe: Change from baseline to 4-6 months and 8-10 months

Trial details

NCT IDNCT03337100

SponsorKaiser Permanente

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-30

View on ClinicalTrials.gov More Overdose trials